Diabetes and Its Correlation with Chronic Kidney Disease (Diabetic Kidney Disease)

1. Epidemiology

• Diabetes is responsible for approximately 44% of new ESKD cases in developed countries.
• In Japan, diabetic nephropathy overtook glomerulonephritis as the leading underlying cause of ESKD since 1997; in China, it has surpassed glomerulonephritis as the leading cause of CKD among hospitalized patients.
• In Singapore, 53% of patients with type 2 diabetes were found to have concomitant CKD in a cross-sectional survey of 1,861 patients.
• Globally, deaths from CKD due to diabetes increased by nearly 107% between 1990 and 2013 (Global Burden of Disease Study).
• The International Diabetes Federation projected the number of adults with diabetes would rise from 415 million (2015) to 642 million by 2040, with the highest growth rates expected in Africa.
• Brenner and Rector's The Kidney, 2-Volume Set, pp. 3381, 3295

2. Pathophysiology - How Diabetes Damages the Kidney

2a. Glomerular Hyperfiltration (Early Stage)

2b. Structural Kidney Lesions

• GBM thickening - the very first change detectable by electron microscopy, developing within 2 years of onset of type 1 diabetes; associated with increased α₃ and α₄ chains of type IV collagen.
• Diffuse mesangial sclerosis - increase in mesangial matrix with mesangial cell proliferation; found in most individuals with >10 years of diabetes. When severe, causes nephrotic syndrome (proteinuria, hypoalbuminemia, edema).
• Nodular glomerulosclerosis (Kimmelstiel-Wilson lesion) - the pathognomonic lesion of diabetic nephropathy; ball-like deposits of laminated matrix in the periphery of the glomerulus, seen in 15-30% of long-term diabetics.

• Hyaline arteriolosclerosis affects both the afferent AND efferent arterioles - efferent arteriolar involvement is virtually unique to diabetes and distinguishes it from hypertensive nephrosclerosis.
• Vascular compromise leads to ischemia and diffuse cortical scarring (nephrosclerosis).

• Both acute and chronic pyelonephritis are more severe in diabetics.
• Necrotizing papilitis (papillary necrosis) is much more prevalent in diabetics.
• Tubular basement membrane thickening also occurs.

• Robbins & Kumar Basic Pathology, pp. 751-752
• Brenner and Rector's The Kidney, pp. 1777-1778

3. Molecular & Genetic Mechanisms

• RAAS activation plays a central role - ACE gene polymorphisms (especially the DD genotype) are associated with higher susceptibility to ESKD.
• Advanced glycation end products (AGEs) from chronic hyperglycemia damage glomerular structures.
• Oxidative stress and inflammation: TNF receptor 1 and 2 are strongly associated with impaired GFR and ESKD progression; MCP-1 (monocyte chemoattractant protein-1) predicts renal function decline; IL-6, IL-10, and ICAM-1 gene polymorphisms have been linked to progression.
• Podocyte injury and loss - progressive reduction in podocyte number correlates with mesangial expansion and GFR decline.
• TGF-β drives extracellular matrix accumulation and fibrosis.
• Microalbuminuria concentrations increase logarithmically at HbA1c levels above 8%.
• Brenner and Rector's The Kidney, pp. 1774, 3381

4. Clinical Stages and Progression

• Brenner and Rector's The Kidney, p. 1776

5. Prognosis and Mortality

• Type 2 diabetes + no kidney disease: ~12% (4.1% excess)
• Type 2 diabetes + albuminuria only: ~25% (17.8% excess)
• Type 2 diabetes + impaired GFR only: ~32% (23.9% excess)
• Type 2 diabetes + both albuminuria AND impaired GFR: ~55% (47% excess)

• Brenner and Rector's The Kidney, p. 1776

6. Management

Glycemic Control

• Intensive glucose control in type 1 diabetes clearly prevents development and progression of DKD.
• In type 2 diabetes, evidence is less certain; treating to HbA1c <7.0% (53 mmol/mol) is not recommended in CKD stages 3-5 due to the risk of severe hypoglycemia counterbalancing benefits.

Blood Pressure Control

• The vast majority of patients with DKD require 3 or more antihypertensive drugs to achieve target BP.
• ACE inhibitors and ARBs are first-line agents - they slow progression at both early (microalbuminuria) and late (proteinuria with reduced GFR) stages, independent of BP-lowering effects.
• Dual RAAS blockade (ACE inhibitor + ARB) is NOT recommended - the VA NEPHRON-D and ONTARGET trials showed increased acute kidney injury and hyperkalemia without benefit.
• The ADVANCE trial showed ACE inhibitor (perindopril) + thiazide diuretic (indapamide) significantly reduces BP and risk of kidney and cardiovascular complications in type 2 diabetes.

SGLT2 Inhibitors

• Reduce intraglomerular hypertension by promoting natriuresis.
• The 2026 network meta-analysis (PMID 41147324) confirms their superiority in renal outcomes among novel antidiabetic agents in T2DM with CKD.
• Current guidelines recommend SGLT2 inhibitors in CKD and non-CKD patients with CVD and/or multiple cardiovascular risk factors alongside RAAS blockade.

GLP-1 Receptor Agonists

• Also reduce cardiovascular events in patients with type 2 diabetes at high cardiovascular risk, with some renoprotective benefit, especially by reducing obesity and BP.

Finerenone (Non-steroidal Mineralocorticoid Receptor Antagonist)

• The FIDELIO-DKD trial (5,734 patients with type 2 diabetes, eGFR 25-75 mL/min/1.73 m²) showed finerenone added to ACE inhibitor or ARB significantly reduced the composite of death, kidney failure, or sustained eGFR decline.
• It significantly reduced cardiovascular mortality and morbidity in DKD compared with placebo.

Lipid Management & Lifestyle

• Dyslipidemia treatment is integral to managing diabetic CKD patients.
• Physical inactivity is associated with albuminuria and cardiovascular mortality - physical activity should be encouraged.
• Smoking is associated with CKD progression in diabetic patients.
• Harrison's Principles of Internal Medicine 22E, p. (Diabetic Nephropathy section)
• Comprehensive Clinical Nephrology, 7th Edition, p. 1144
• National Kidneys Foundation Primer on Kidney Diseases, 8e

7. Biomarkers for Monitoring

8. Summary Table